# China NMPA Drug Inspection - Tianjin Boai Biopharmaceutical Co., Ltd. - raw milk

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/tianjin-boai-biopharmaceutical-co-ltd/4faef049-5389-42e6-90fe-7eaccbf469ef/
Source feed: China

> China NMPA drug inspection for Tianjin Boai Biopharmaceutical Co., Ltd. published July 27, 2020. Drug: raw milk. On July 27, 2020, the Hebei Provincial Drug Administration released its 2020 Drug Supervision and Sampling Inspection Bu

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Hebei Province Drug Quality Bulletin (2020 Drug Supervision and Sampling Inspection No. 2)
- Company Name: Tianjin Boai Biopharmaceutical Co., Ltd.
- Publication Date: 2020-07-27
- Drug Name: raw milk
- Inspection Finding: [Inspection] The filling quantity under this item does not meet the requirements.
- Action Taken: Relevant drug regulatory authorities and market supervision authorities have taken control measures such as sealing and seizing goods in accordance with the law. Investigations have been launched into cases involving the illegal production and sale of substandard products, and necessary risk control measures have been implemented.
- Summary: On July 27, 2020, the Hebei Provincial Drug Administration released its 2020 Drug Supervision and Sampling Inspection Bulletin (No. 2), detailing non-compliance found during quality checks of manufacturers, distributors, and healthcare providers. The inspections identified two companies for significant quality failures. Tianjin Boai Biopharmaceutical Co., Ltd. was cited for a batch of raw breast milk (batch 190501) that failed fill quantity standards. Additionally, Anguo Qiao Traditional Chinese Medicine Pieces Co., Ltd. produced Arborvitae seed kernel (batch 1809344133) that was found to be infested with insects, violating appearance standards. These enforcement actions were conducted under the regulatory framework of the Drug Administration Law of the People's Republic of China. In response to these violations, authorities have seized the substandard products and ordered local departments to investigate and prosecute the enterprises for the illegal production and sale of non-compliant drugs. Required actions include implementing risk control measures, investigating potential counterfeit distribution channels, and referring any suspected criminal behavior to public security departments for prosecution. This bulletin emphasizes the administration's ongoing efforts to maintain pharmaceutical safety through rigorous surveillance and law enforcement.

Company: https://www.globalkeysolutions.net/companies/tianjin-boai-biopharmaceutical-co-ltd/5669f366-5882-4dd7-ac05-0422ea178716/